SCHEMBL6949089

SCHEMBL6949089

CSc1nc(OCCN2CCOCC2)c(C#N)c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.40
ALDH1A1 P00352 12/20 0.39
HTT P42858 5/20 0.39
NPSR1 Q6W5P4 4/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 2/20 0.39
HPGD P15428 5/20 0.38
SIGMAR1 Q99720 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 6/20 0.38
LMNA P02545 5/20 0.38
HIF1A Q16665 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 1/20 0.37
ADORA2A P29274 1/20 0.37
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949790 0.84 ALDH1A1 (0.41) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL6955347 0.82 LMNA (0.51) ALDH1A1NPSR1MAPK1HSD17B10TSHR
SCHEMBL6953029 0.82 GRM2 (0.40) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL6949293 0.82 MEN1 (0.39) ALDH1A1HTTHSD17B10HPGDMEN1
SCHEMBL6947632 0.81 PIK3CD (0.39) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL6955735 0.80 ADRA2A (0.38) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL6949864 0.80 HRH4 (0.36) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL11836332 0.79 ALDH1A1 (0.48) ALDH1A1HTTNPSR1MAPK1HSD17B10
SCHEMBL6956323 0.78 MKNK1 (0.47) MKNK1ALDH1A1HTTHSD17B10TSHR
SCHEMBL11826232 0.77 ALDH1A1 (0.50) ALDH1A1HTTNPSR1MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed